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Mycobacterium tuberculosis (M.tb) infection results in approximately 1.3 million human
deaths each year. M.tb resides primarily inside macrophages, and maintains persistent
infection. In response to infection and inflammation, platelet activating factor C-16 (PAF
C-16), a phospholipid compound, is released by various cells including neutophils
and monocytes. We have recently shown that PAF C-16 can directly inhibit the
growth of two representative non-pathogenic mycobacteria, Mycobacterium bovis
BCG and Mycobacterium smegmatis (M. smegmatis), by damaging the bacterial cell
membrane. Here, we have examined the effect of PAF C-16 on M. smegmatis residing
within macrophages, and identified mechanisms involved in their growth inhibitory
function. Our results demonstrated that exogenous PAF C-16 inhibited the growth
of M. smegmatis inside phagocytic cells of monocytic cell line, THP-1; this effect
was partially blocked by PAF receptor antagonists, suggesting the involvement of PAF
receptor-mediated signaling pathways. Arachidonic acid, a downstream metabolite of
PAF C-16 signaling pathway, directly inhibited the growth of M. smegmatis in vitro.
Moreover, the inhibition of phospholipase C and phospholipase A2 activities, involved
in PAF C-16 signaling pathway, increased survival of intracellular M. smegmatis.
Interestingly, we also observed that inhibition of inducible nitric oxide synthase
(iNOS) enzyme and antibody-mediated neutralization of TNF-α partially mitigated the
intracellular growth inhibitory effect of PAF C-16. Use of a number of PAF C-16
structural analogs, including Lyso-PAF, 2-O-methyl PAF, PAF C-18 and Hexanolamino
PAF, revealed that the presence of acetyl group (CH3CO) at sn-2 position of the
glycerol backbone of PAF is important for the intracellular growth inhibition activity
against M. smegmatis. Taken together, these results suggest that exogenous PAF C-
16 treatment inhibits intracellular M. smegmatis growth, at least partially, in a nitric oxide
and TNF-α dependent manner.
Keywords: platelet activating factor, PAF analogs, Mycobacterium tuberculosis, Mycobacterium smegmatis, THP-
1 cells, intracellular mycobacterial growth
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INTRODUCTION
Mycobacterium tuberculosis (M.tb) belongs to the acid-fast group
of bacteria and causes an infectious disease in humans, known as
Tuberculosis (TB), which mostly affects the respiratory system.
Approximately 1.3 million people died as a result of M.tb
infections in 2017, which is the highest number of human
mortalities caused by any single bacterial pathogen (World
Health Organization [WHO], 2018). Nearly 10 million new cases
of M.tb infection were reported worldwide during 2017, the
majority of infected population belongs to developing countries
such as India, Indonesia, China, the Philippines, Pakistan,
and Nigeria (World Health Organization [WHO], 2018). It is
estimated that about one-third of the world’s population are
latently infected with M.tb (Flynn and Chan, 2001). The latently
infected individuals show no evidence of active disease due to the
containment of the pathogen by the host immune system. Over
the course of time, this latent M.tb infection can reactivate into
active disease, and thus, provides a vast reservoir for the spread
of M.tb infection.
New challenges such as HIV-1 and M.tb co-infections in
TB patients, multi-drug resistant (MDR), and extensively drug
resistant (XDR) strains of M.tb have also emerged recently.
During HIV-1 and M.tb co-infection, the virus infects the CD4+T
cells, which are the most important immune cells involved in
controlling M.tb infection (Daley et al., 1992). The HIV infection,
thus, not only predisposes the patients to new M.tb infections,
but also increases the chances of reactivation of latent TB
due to host’s immunocompromised status. The emergence of
MDR and XDR strains of M.tb is a global challenge in treating
TB patients as the patients fail to respond to multiple anti-
TB drugs, and hence, can act as a reservoir for the spread
of drug-resistant M.tb strains (Espinal et al., 2000; Ormerod,
2005; Liu et al., 2011). The current vaccine against TB consists
of attenuated Mycobacterium bovis strain, Bacillus Calmette-
Guéerin (BCG), which is almost 100 years old with variable
efficacy, and is not effective in the adult population (Sepulveda
et al., 1992; Colditz et al., 1994; Aronson et al., 2004; Lahey
and von Reyn, 2016). Therefore, to control the global menace
of TB, novel interventions are required on the therapeutic and
preventive fronts.
Mycobacterium tuberculosis infection of the host evokes
localized inflammation in the lungs, resulting in the migration
of different immune cells and the leakage of plasma proteins and
non-proteinaceous factors at the site of infection due to changes
in vascular permeability (Sherwood and Toliver-Kinsky, 2004;
Amaral et al., 2016). In addition, phospholipids, such as PAF
C-16 and proteins such as C1q, are synthesized by the host’s
immune cells, which are present at the site of infection (Camussi
et al., 1987; Kaul and Loos, 1995). These host factors are likely to
come in direct contact with the bacterial pathogen and immune
cells, and thus, may modulate the outcome of the infection. The
effects of the majority of these host factors on M.tb growth,
intracellular as well as extracellular, are either poorly understood
or completely unknown.
Platelet activating factor (PAF) is a phospholipid compound
that is involved in a number of important biological processes in
mammals, including platelet aggregation (Chesney et al., 1982),
inflammation and allergy (Henderson et al., 2000). Chemically,
PAF is 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphocholine
(Demopoulos et al., 1979). The most common form of naturally
produced PAF in humans contains a 16-carbon chain attached
at the sn-1 position via ether linkage, and is known as PAF C-16
(Clay et al., 1984). PAF C-16 is normally present in picogram
per milliliter concentrations in human serum; however, its
production is increased during inflammation, allergic reactions
and in newly diagnosed TB patients, particularly in cavitary
form of pulmonary TB (Kaminskaia and Aladysheva, 1995;
Vadas et al., 2013). Moreover, neutrophils from TB patients,
when stimulated with BCG in vitro, produced three times more
PAF C-16 than control (Kaminskaia and Aladysheva, 1995).
A variety of cell types including platelets (Alam et al., 1983),
monocytes/macrophages (Leaver et al., 1990; Yagnik, 2014),
neutrophils (Biffl et al., 1996), endothelial cells (Bussolino
et al., 1986), and mast cells (Schleimer et al., 1986) are able
to produce PAF C-16 upon stimulation. PAF C-16 binds to a
specific G-protein coupled receptor, PAF receptor (PAFR), on the
target cells (Ishii et al., 2002). PAF-PAFR engagement activates
downstream signaling pathways, including the activation of
phospholipases (PLC and PLA2), kinases such as protein tyrosine
kinase and protein kinase C as well as the production of cytokines
such as TNF-α, IL-1α and prostaglandins (Ishii and Shimizu,
2000; Honda et al., 2002).
It has been shown that PAF C-16 possesses direct growth
inhibition activity against mycobacteria (M. smegmatis and
M. bovis BCG) (Riaz et al., 2018) and a number of Gram-
positive bacteria (Steel et al., 2002) by causing damage to the
cell membrane. Exogenous PAF C-16 has also been shown to
inhibit the growth of intracellular pathogenic protozoans such
as Leishmania and Trypanosoma inside human and mouse
macrophages by causing the production of reactive oxygen and
nitrogen species (Aliberti et al., 1999; Lonardoni et al., 2000;
Borges et al., 2017). Similarly, administration of exogenous PAF
C-16 in mice, infected with lethal doses of Candida albicans,
reduced the number of pathogens and improved the survival via
production of NO and TNF-α (Im et al., 1997; Kim et al., 2008).
In the current study, we examined PAF C-16 and its structural
analogs in vitro for their effect on the growth of M. smegmatis
(as a model for M.tb) inside human monocytes derived THP-
1 cells. Furthermore, the underlying mechanisms of PAF C-16





choline) and different PAF C-16 structural analogs, including
Lyso-PAF (1-O-hexadecyl-2- hydroxy-sn-glyceryl-3-phosphoryl
choline), PAF C-18 (1-O-octadecyl-2-O-acetyl-sn-glyceryl-
3-phosphorylcholine), Hexanolamino PAF [1-O-hexadecyl-2-O-
acetyl-sn-glyceryl-3-phosphoryl (N,N,N-trimethyl) hexanol
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FIGURE 1 | Chemical structures of PAF C-16 and its various analogs tested
against M. smegmatis. The changes in structure for different analogs are
highlighted in red circles.
amine], 2-O-methyl PAF (1-O-hexadecyl-2-O-methyl-sn-
glyceryl-3-phosphorylcholine), as shown in Figure 1, along
with ABT-491 (1-(N,N-Dimethylcarbamoyl)-4-ethynyl-3-(3-
fluoro-4-((1H-2-methylimidazo[4,5-c]pyridin-1-yl)methyl)
benzoyl)-indole, HCl), U-73122 (1-[6-[((17β)-3-Methoxyestra-
1,3,5[10]-trien-17-yl)amino]hexyl]-1H-pyrrole-2,5-dione) and
arachidonic acid were purchased from Cayman Chemical
Company, United States. WEB-2086 (3-[4-(2-Chlorophenyl)-
9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-
2-yl]-1-(4-morpholinyl)-1-propanone), benzenesulfonamide
and aminoguanidine hemisulfate were purchased from Sigma-
Aldrich Company, United States. All the chemicals used in
different experiments were of analytical grade.
Stock solutions of PAF C-16, PAF C-16 structural analogs,
WEB-2086, U-73122 and arachidonic acid were prepared in
ethanol according to the manufacturer’s protocol. ABT-491 and
aminoguanidine hemisulfate stock solutions were prepared using
distilled water; while the stock solution of benzenesulfonamide
was prepared in methanol. Appropriate solvent controls were
included in all the experiments involving PAF C-16, its structural
analogs or any other chemical compound used.
Culturing of M. smegmatis
M. smegmatis (mc2 155) were grown in Luria-Bertani (LB)
broth (Lennox; Sigma Aldrich) containing 50 µg/ml carbenicillin
(Fisher Scientific, United Kingdom), 0.15% (v/v) glycerol (Fisher
Scientific, United Kingdom) and 0.10% (v/v) Tween-80 (Fisher
Scientific, United Kingdom) in a shaking incubator at 37◦C until
the O.D600 nm reached 0.8–0.9. The number of M. smegmatis
colony forming units (CFUs) per µl was determined by plating
different dilutions of the bacterial stock on LB agar plates in
triplicates and counting the number of CFUs after incubation at
37◦C for 72 h.
The LB agar plates for growing M. smegmatis colonies
were prepared by dissolving tryptone (10 g) (Fisher
Scientific, United Kingdom), yeast extract (5 g) (Fisher
Scientific, United Kingdom), sodium chloride (0.5 g) (Fisher
Scientific, United Kingdom) and agar (15 g) (Fisher Scientific,
United Kingdom) in 1 Litre distilled water and autoclaving the
media at 121◦C for 15 min. About 15–20 ml of melted LB agar
was poured in each plate (petri dish) under sterile conditions and
the plates were allowed to solidify for 90–120 min before plating
M. smegmatis.
THP-1 Cell Culture
THP-1 cells (a human monocytic leukemic cell line; ATCC R©
TIB-202TM), used as the model phagocytic cells, were grown
in complete RPMI (cRPMI) medium at 37◦C using an
incubator with 5% CO2 supply. The cRPMI medium was
prepared by adding 10% v/v fetal bovine serum (FBS)
(HyClone, United Kingdom), 1 mM sodium pyruvate (Sigma
Aldrich, United Kingdom), 2 mM L-glutamine (Sigma Aldrich,
United Kingdom) and PenStrep (100 U/mL Penicillium and
100 µg/mL Streptomycin) (Sigma Aldrich, United Kingdom)
to RPMI-1640 (Sigma Aldrich, United Kingdom). Cells were
fed every 3 days by removing half of the culture medium and
replacing it with fresh cRPMI; the cell density was kept at about
0.5–0.75× 106/ml.
Intracellular Growth Inhibition Assay for
M. smegmatis Using THP-1 Cells
Intracellular bacterial growth inhibition assays were performed to
investigate the effect of different test compounds, including PAF
C-16 and PAF structure analogs, on the growth of phagocytosed
M. smegmatis inside THP-1 cells. THP-1 cells, grown at a density
of 0.5–0.75 × 106/ml, were washed twice with plain RPMI
medium and adjusted to ∼0.25 × 106 cells/ml in cRPMI without
antibiotics. One ml of this cell suspension was added to individual
Eppendorf tubes. Approximately 1.25 × 106 M. smegmatis
(bacteria to THP1 ratio; 5:1) was then added to each tube. These
tubes were incubated at 37◦C in a CO2 incubator for 2 h with
intermittent shaking to allow phagocytosis of bacteria.
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FIGURE 2 | Effect of PAF C-16 treatment on the growth of intracellular
M. smegmatis. M. smegmatis infected THP-1 cell were treated for 24 h with
either solvent control (10 µl ethanol/ml) or indicated concentrations of PAF
C-16, before lysis and plating. The data shown as box plots represent
median, interquartile and minimal and maximal values for four individual
experiments performed in triplicates. The data is expressed in terms of
percentage, where solvent control is considered as 100% survival. Level of
significance was calculated by applying multiple comparison non-parametric
Kruskal–Wallis test on ranks (p = 0.0012) and any two data sets were
compared using post hoc Dunn’s multiple comparison, where PAF C-16
(1 µg/ml) vs solvent control was found to be significant, **p ≤ 0.01.
Pan anti-mouse IgG coated magnetic Dynabeads (Thermo
Fisher Scientific, United Kingdom), bound to mouse pan anti-
human MHC class I (HLA A, B, and C) antibody W6/32
(BioLegend, United States), were prepared to remove non-
phagocytosed M. smegmatis. For each sample, 106 Dynabeads
were incubated with 1 µg of W6/32 for 90 min on ice to
allow the binding of the beads with W6/32 antibody. Later, the
beads were washed twice with plain RPMI by applying a Dynal R©
magnet (Thermo Fisher Scientific, United Kingdom) and this
reagent (Dynabeads-W6/32) was resuspended in 25 µl of RPMI.
The ‘Dynabeads-W6/32’ were then added to the previously
prepared tube, containing THP-1 cells with M. smegmatis (beads
to cells ratio; 4:1). The Eppendorf tubes were then placed on
ice for 45 min with intermittent shaking to allow the binding
of W6/32 component of ‘Dynabeads-W6/32’ with MHC Class I
molecules present on THP-1 cells. After incubation, extracellular
M. smegmatis was removed by applying a Dynal R© magnet and
washing the cells twice with plain RPMI. This was followed by
resuspending the cells in 1ml cRPMI without antibiotic. For
each experiment, a solvent control and test compounds treated
samples were included and the tubes were incubated at 37◦C
in a CO2 incubator for another 24 h. After incubation, Dynal R©
magnet was applied to the Eppendorf tubes. The ‘Dynabeads-
W6/32’attached to THP-1 cells migrated to the side of Eppendorf
tube. The supernatant was removed and stored in 15 ml falcon
tubes to collect any extracellular bacteria released from dying
cells. The THP-1 cells left in the Eppendorf tubes were lysed by
adding 1ml of 1% w/v saponin solution in water (Fisher Scientific,
United Kingdom) and vortexing the mixture for 15 min. The cell
lysate for each condition was transferred to the respective 15 ml
falcons already containing 1 ml of bacterial supernatant that was
collected earlier. The contents of each falcon tube were mixed by
vortexing for 10 s and serial dilutions (10−1, 10−2, and 10−3)
were prepared in sterile PBS.
Finally, the bacterial suspensions, at dilutions of 10−2 and
10−3, were used for plating. 200 µl of bacterial suspension was
plated for each experimental condition in triplicates using LB-
agar plates. Plates were incubated at 37◦C for 72 h, after which
the number of bacterial CFUs were counted. A comparison of
CFUs between test compound treated plates and the solvent
control was done to determine the effect of the test compound
on the growth of intracellular M. smegmatis inside THP-
1 cells.
Assessing the Effects of PAF Receptor
Antagonists on PAF C-16 Induced
Intracellular M. smegmatis Growth
Inhibition
Two PAFR antagonists, ABT-491 and WEB-2086, were used
to examine their effects on PAF C-16 induced intracellular
M. smegmatis growth inhibition. The assays were carried out
according to the intracellular growth inhibition assay as described
above, with a difference that M. smegmatis infected THP-1 cells
were initially treated with PAFR antagonists (ABT-491 or WEB-
2086, 2 µg/ml each) for 1 h before adding PAF C-16 (1 µg/ml)
to the cell culture, the samples were incubated further for 24 h
at 37◦C in a CO2 incubator. Solvent control along with an
additional control comprising of M. smegmatis infected THP-1
cells treated with PAFR antagonists only, were also included in
the experimental design.
Assessing the Effects of Chemical
Inhibitors of PLC, PLA2 and iNOS and
Anti-TNF-α Antibody on PAF C-16
Induced Intracellular M. smegmatis
Growth Inhibition
Assays using inhibitors of PLC (U-73122), cPLA2
(benzenesulfonamide) and iNOS (aminoguanidine hemisulfate)
were also performed similar to the intracellular growth
inhibition assay. The only difference was in the treatment
step where M. smegmatis infected THP-1 cells were first
treated with U-73122 (2 µM) (Macmillan and McCarron,
2010), benzenesulfonamide (56 nM) (Farooqui et al., 2006)
or aminoguanidine hemisulfate (1 mM) (Nascimento
et al., 2002) for 1 h. Subsequently, PAF C-16 (1 µg/ml)
was added and the THP-1 cells containing phagocytosed
M. smegmatis were further incubated for 24 h at 37◦C
in a CO2 incubator. An additional control comprising of
M. smegmatis infected THP-1 cells treated with U-73122
(2 µM), benzenesulfonamide (56 nM) or aminoguanidine
hemisulfate (1 mM), was also included in the respective
experimental designs.
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FIGURE 3 | Effect of PAF C-16 structural analogs on the growth of intracellular M. smegmatis. M. smegmatis infected THP-1 cells were treated for 24 h with either
solvent control (10 µl ethanol/ml), Lyso-PAF (A), 2-O-methyl PAF (B), PAF C-18 (C) or Hexanolamino PAF (D) at indicated concentrations, before lysis and plating.
The data is expressed in terms of percentage, where solvent control is considered as 100% survival. The data shown as box plots represent median, interquartile
and minimal and maximal values for four individual experiments performed in triplicates. Statistically significant differences between tests samples (PAF analogs)
versus solvent controls were determined using Kruskal–Wallis test and any two data sets were compared using post hoc Dunn’s multiple comparison (**p ≤ 0.01
and *p ≤ 0.05).
Anti-TNF-α neutralizing antibody (BD Biosciences,
United States) was used to investigate the role of TNF-
α in PAF C-16 induced growth inhibition of intracellular
M. smegmatis. M. smegmatis infected THP-1 cells were treated
with 10 µg/ml of mouse anti-human TNF-α antibody, an isotype
antibody control (10 µg/ml mouse IgG) or ethanol (PAF C-16
solvent) for 1 h prior to treatment with 1 µg/ml PAF C-16, and
the cells were further incubated for another 24 h before cell
lysis and plating.
Direct Growth Inhibition Assay
This assay was carried out as described previously (Riaz et al.,
2018), to investigate the direct effect of arachidonic acid on
M. smegmatis growth. Briefly, the diluted stock of M. smegmatis
(2.5 × 104) in suspensions of 1ml LB broth was exposed
to a range of concentrations of arachidonic acid for 2 h at
37◦C with mixing every 15 min. Appropriate solvent control
(10 µl/ml) for the test compound was included. After incubation,
200 µl of bacterial suspensions from test and control tubes
were seeded on LB agar plates in triplicate and the plates
were incubated at 37◦C for 72 h. Colony counting method
was used to detect the direct growth inhibitory effects of the
test compounds.
Statistical Analysis
At least three independent experiments were performed.
The data were presented as box plots of medians (25th-
75th percentile), and the solvent treated samples (control)
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FIGURE 4 | Effect of PAFR antagonists (ABT-491 and WEB-2086) on PAF
C-16 induced growth inhibition of intracellular M. smegmatis. M. smegmatis
infected THP-1 samples were treated for 24 h with either solvent control
(10 µl ethanol/ml), ABT-491 (2 µg/ml), PAF C-16 (1 µg/ml) and a combination
of ABT-491 (2 µg/ml) and PAF C-16 (1 µg/ml) (Test-1) (A), or WEB-2086
(2 µg/ml) and a combination of WEB-2086 (2 µg/ml) and PAF C-16 (1 µg/ml)
(Test-2) (B), before lysis and plating. The data is expressed in terms of
percentage, where solvent control is taken as 100% survival and different
treated conditions are compared to it. The data shown as box plots represent
median, interquartile and minimal and maximal values for four individual
experiments performed in triplicates. Statistically significant (*p = 0.02)
differences were found in the case of both PAFR antagonists with PAF C-16
alone treated samples using Mann–Whitney test.
were considered 100% bacterial survival. Statistical analysis
was performed using GraphPad Prism R© software (Version
5.01) to determine the level of significance (p-value).
For intracellular growth inhibition assays, p-value was
determined by applying non-parametric multiple comparison
Kruskal–Wallis test on ranks and any two datasets were
compared using Dunn’s post hoc test. For comparison of
two particular datasets, non-parametric Mann–Whitney
test was used. A p-value of less than or equal to 0.05
FIGURE 5 | Effect of PLC inhibitor U-73122 on PAF C-16 induced growth
inhibition of intracellular M. smegmatis. M. smegmatis infected THP-1
samples were treated for 24 h with either solvent control (10 µl ethanol/ml),
U-73122 (2 µM), PAF C-16 (1 µg/ml) or a combination of U-73122 (2 µM) and
PAF C-16 (1 µg/ml) (Test), before lysis and plating. The data is expressed in
terms of percentage, where solvent control is taken as 100% survival and
different treated conditions are compared to it. The data represent median,
interquartile and minimal and maximal values for four individual experiments
performed in triplicates. Statistically significant (*p = 0.02) difference was
found for Test v 1 µg/ml PAF C-16 using Mann–Whitney test.
FIGURE 6 | Effect of cPLA2 inhibitor Benzenesulfonamide on PAF C-16
induced growth inhibition of intracellular M. smegmatis. M. smegmatis
infected THP-1 samples were treated for 24 h with either solvent control
(10 µl ethanol/ml), Benzenesulfonamide (BS, 56 nM), PAF C-16 (1 µg/ml) or a
combination of BS (56 nM) and PAF C-16 (1 µg/ml) (Test), before lysis and
plating. The data is expressed in terms of percentage, where solvent control is
taken as 100% survival and different treated conditions are compared to it.
The data represent median, interquartile and minimal and maximal values for
four individual experiments performed in triplicates. Statistically significant
(*p = 0.02) difference was found for Test v 1 µg/ml PAF C-16 only treated
condition using Mann–Whitney test.
(p ≤ 0.05) was considered to be significant. On the
graphs, p ≤ 0.05 was denoted by ∗, p ≤ 0.01 by ∗∗, and
p ≤ 0.001 by ∗∗∗.
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FIGURE 7 | Direct effect of Arachidonic acid on M. smegmatis growth in vitro.
M. smegmatis samples were directly treated either with solvent control (10 µl
ethanol/ml) or indicated concentrations of arachidonic acid for 2 h before
plating. Data is expressed in percentage where solvent control is taken as
100% survival and different arachidonic acid treated conditions are compared
to it. The data represent median, interquartile and minimal and maximal values
for three individual experiments performed in triplicates. Statistically significant
differences between arachidonic acid treated and solvent control samples
were estimated using Kruskal–Wallis test (p = 0.004) and any two sets of data
were compared using post hoc Dunn’s multiple comparison. **p ≤ 0.01 and
***p ≤ 0.001.
RESULTS
PAF C-16 Suppresses M. smegmatis
Growth Inside THP-1 Cells
Intracellular growth inhibition assays were performed by
treating M. smegmatis infected THP-1 cells with PAF C-16
at concentrations ranging between 0.001–10 µg/ml (1.90 nM–
19.09 µM) for 24 h and the resulting growth inhibitory effect was
determined by counting the number of surviving CFUs on LB
agar plates. PAF C-16, at a concentration of 1 µg/ml (1.90 µM),
on average inhibited the growth of intracellular M. smegmatis
by 49% (n = 4, independent experiments), compared with the
solvent control (10 µl ethanol/ml cell suspension) (p ≤ 0.01)
(Figure 2). Treatment of M. smegmatis infected THP-1 cells
with PAF C-16 at concentrations higher or lower than 1 µg/ml
[0.001 µg (1.90 nM), 0.01 µg (19.09 nM), 0.1 µg (190.9 nM),
5 µg (9.5 µM), and 10 µg/ml (19.09 µM)] for 24 h showed
no significant inhibitory effect on the growth of intracellular
M. smegmatis (Figure 2).
Acetyl Group at sn-2 Position Is Essential
for the Inhibitory Effect of PAF C-16 on
M. smegmatis Growth Inside THP-1 Cells
To assess the impact of small modifications in the structure of
PAF C-16 on its intracellular M. smegmatis growth inhibition
potential, different PAF C-16 structural analogs, including its
precursor form Lyso-PAF, 2-O-methyl PAF, PAF C-18 and
Hexanolamino PAF (Figure 1) were tested. The results showed
that structural analogs lacking an acetyl group at sn-2 position
such as Lyso-PAF and 2-O-methyl PAF were unable to inhibit
the growth of intracellular M. smegmatis at concentrations range
of 1, 5, and 10 µg/ml (Figures 3A,B). Both PAF C-18 and
Hexanolamino PAF having acetyl group at sn-2 position were
able to inhibit the growth of intracellular M. smegmatis at the
concentration of 1 and 5 µg/ml, respectively (p ≤ 0.01 and
p ≤ 0.05) (Figures 3C,D), and their intracellular M. smegmatis
growth inhibition ability was similar to PAF C-16 at 1 µg/ml
(∼50% reduction in CFUs).
PAF Receptor Antagonists Partially
Mitigated PAF C-16 Induced Intracellular
M. smegmatis Growth Inhibition
Two structurally distinct PAFR antagonists, ABT-491 and WEB-
2086, were used to investigate their effect on PAF C-16
induced growth inhibition of M. smegmatis. Prior treatment of
M. smegmatis infected THP-1 cells with ABT-491 or WEB-2086
(Test-1 and Test-2, Figure 4) at a concentration of 2 µg/ml
partially mitigated the inhibitory effect of PAF C-16 on the
growth of intracellular M. smegmatis, as indicated by an increase
in the of number CFUs (20–24.5%) compared to 1 µg/ml PAF
C-16 treated only condition (n = 4, independent experiments)
(Figures 4A,B). This difference was significant (p = 0.02, Mann–
Whitney test) for both PAFR antagonists. In the absence of PAF
C-16, ABT-491 as well as WEB-2086 showed no effect on the
survival of intracellular M. smegmatis (Figures 4A,B).
PLC Inhibitor (U-73122) Partially
Overcomes PAF C-16 Induced
Intracellular M. smegmatis Growth
Inhibition
PAF C-16 binding to its receptor causes the activation of
phospholipase C (PLC). PLC inhibitor, U-73122, was therefore,
used to investigate the role of PLC in PAF C-16 induced growth
inhibition of intracellular M. smegmatis. It was observed that
U-73122 at a concentration of 2 µM was effective in partially
mitigating the inhibitory effect PAF C-16 on the growth of
intracellular M. smegmatis. Treatment of M. smegmatis infected
THP-1 cells with U-73122 along with 1 µg/ml PAF C-16 resulted
in ∼25.2% increase in the number of surviving M. smegmatis
CFUs when compared to 1 µg/ml PAF C-16 only treated
condition (Figure 5); this difference was significant (p = 0.02,
Mann–Whitney test).
PLA2 Inhibitor (Benzenesulfonamide)
Partially Overcomes PAF C-16 Induced
Intracellular M. smegmatis Growth
Inhibition
PAF C-16 also causes the activation of cytosolic phospholipase
A2 (cPLA2), which leads to the intracellular production
of arachidonic acid (AA) and lysophosphatidylcholine.
Benzenesulfonamide, a cPLA2 inhibitor, was used to
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FIGURE 8 | Effect of Aminoguanidine hemisulfate treatment on PAF C-16
induced intracellular M. smegmatis growth inhibition. M. smegmatis infected
THP-1 cells were treated for 24 h either with solvent control (10 µl ethanol/ml),
Aminoguanidine hemisulfate (AG, 1 mM), PAF C-16 (1 µg/ml) or a
combination of AG (1 mM) and PAF C-16 (1 µg/ml) (Test), before lysis and
plating. The data is expressed in terms of percentage, where solvent control is
considered as 100% survival and different treatment conditions are compared
to it. The data represent median, interquartile and minimal and maximal values
for four individual experiments performed in triplicates. Statistically significant
(*p = 0.02) difference was found for Test v 1 µg/ml PAF C-16 using
Mann–Whitney test.
FIGURE 9 | Effect of anti-TNF-α neutralizing antibody on PAF C-16 induced
intracellular M. smegmatis growth inhibition. M. smegmatis infected THP-1
cells were treated for 24 h with solvent control (10 µl ethanol/ml), anti-TNFα
antibody (10 µg/ml), PAF C-16 (1 µg/ml), a combination of isotype control
antibody (10 µg/ml) with PAF C-16 (1 µg/ml) and anti-TNFα antibody
(10 µg/ml) with PAF C-16 (1 µg/ml) (Test), before lysis and plating. The data is
expressed in terms of percentage, where solvent control is considered as
100% survival and different treatment conditions are compared to it. The data
represent median, interquartile and minimal and maximal values for four
individual experiments performed in triplicates. Statistically significant
(*p = 0.02) differences were found for ‘Test’ v 1 µg/ml PAF C-16 and ‘Test’ v
Isotype control condition using Mann-Whitney test.
investigate the role of cPLA2 in PAF C-16 induced growth
inhibition of intracellular M. smegmatis. M. smegmatis infected
THP-1 cells were treated with benzenesulfonamide at a
concentration of 56nM along with 1 µg/ml PAF C-16 for 24 h.
Benzenesulfonamide partially mitigated the inhibitory effect PAF
C-16 on the growth of intracellular M. smegmatis as indicated by
an increase in the number of surviving M. smegmatis CFUs. On
average, this compound increased the number of M. smegmatis
CFUs by ∼30.1% when compared to the number of CFUs from
1 µg/ml PAF C-16 only treated condition (Figure 6), and this
difference was significant (p = 0.02, Mann–Whitney test).
Arachidonic Acid (AA) Directly Inhibits
M. smegmatis Growth in vitro
AA is produced by activated cPLA2 from intracellular
phospholipids during PAF C-16 signaling pathway. This
compound was investigated in vitro for its direct effect on the
growth of M. smegmatis and the results showed dose-dependent
growth inhibition of M. smegmatis in all the three independent
experiments. AA at the concentrations of 5 and 2.5 µg/ml caused
a reduction of 99 and 86.4%, respectively in the number of
surviving M. smegmatis CFUs as compared to solvent control
(Figure 7); these results were found to be significant (p ≤ 0.001
and p ≤ 0.01, respectively) using Dunn’s multiple comparison
test. Similarly, other intracellular molecules, Phosphoinositol
bisphosphate (PIP2) and Diacylglycerol (DAG) produced
during PAF C-16 signaling were also tested in vitro at the
concentrations of 5, 10, 25, 50, and 100 µg/ml, however, they
showed no direct inhibitory effect on M. smegmatis growth
(Supplementary Figures 3, 4).
Nitric Oxide Synthase Inhibitor
(Aminoguanidine Hemisulfate) Partially
Overcomes PAF C-16 Induced Growth
Inhibition of Intracellular M. smegmatis
Treatment of M. smegmatis infected THP-1 cells with iNOS
inhibitor, aminoguanidine hemisulfate (1 mM), partially
mitigated PAF C-16 induced growth inhibition of intracellular
M. smegmatis. On an average, prior treatment of THP-1 cells
having phagocytosed M. smegmatis with 1 mM AG increased
the number of surviving M. smegmatis CFUs by 23.4% when
compared to 1 µg/ml PAF C-16 only (Figure 8) and this
difference was significant (p = 0.02, Mann–Whitney test).
Anti-TNF-α Antibody Partially Overcomes
PAF C-16 Induced Intracellular
M. smegmatis Growth Inhibition
To investigate the role of TNF-α on PAF C-16 induced
intracellular growth inhibition, M. smegmatis infected THP-1
cells were incubated with 10 µg/ml mouse anti-human TNF-
α monoclonal antibody (neutralizing antibody) and 1 µg/ml
PAF C-16 for 24 h. This antibody partially mitigated the PAF
C-16 induced growth inhibition of intracellular M. smegmatis,
as indicated by 17 and 18% increase in the number of surviving
CFUs as compared to the isotype control antibody (10 µg/ml
mouse IgG + 1 µg/ml PAF C-16) and 1 µg/ml PAF C-16 only
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FIGURE 10 | Proposed mechanism of PAF C-16 induced growth inhibition of intracellular M. smegmatis. Binding of PAF C-16 to its receptor PAFR on the target cell
activates phosphatidylinositol specific phospholipase C (PI-PLC) enzyme which causes the production of second messengers IP3 and DAG inside the cell. The
second messenger IP3 then causes the mobilization of intracellular Ca++. DAG along with Ca++ further leads to the activation of phosphokinase C (PKC) enzyme
that upregulates the production of reactive nitrogen intermediates and TNF-α, which can inhibit the growth of intracellular M. smegmatis. In addition, the elevated
level of intracellular Ca++ also causes the activation of cytosolic phospholipase A2 (cPLA2) enzyme that hydrolyzes phospholipids and results in the production of
arachidonic acid inside the cell. This arachidonic acid has the potential to inhibit the growth of M. smegmatis.
treated conditions respectively (Figure 9) (p = 0.02, Mann–
Whitney test). Furthermore, neutralizing antibodies specific to
IL-6 and IL-10 showed no effect on the intracellular growth
inhibitory effect of PAF C-16 (Supplementary Figures 1, 2).
DISCUSSION
PAF C-16 is a pro-inflammatory phospholipid; its production
increases during inflammation (Gawaz et al., 2005) and bacterial
infections including M.tb infection (Kaminskaia and Aladysheva,
1995; Huseyinov et al., 1999). In this study, the effect of
exogenous PAF C-16 was investigated in vitro on the growth of
intracellular mycobacteria. Phagocytic THP-1 cells infected with
M. smegmatis were used as a model to investigate the intracellular
growth inhibitory effect of PAF C-16. THP-1 cells are human
leukemia derived monocytic cells that mimic blood-derived
monocytes and are a valuable tool for research because of their
homogenous genetic background (Chanput et al., 2014). THP-
1 cells have previously been used as an in vitro model to study
intracellular mycobacteria (Rajavelu and Das, 2007; Fontán et al.,
2008; Rohan et al., 2008; Iona et al., 2012). THP-1 cells are usually
treated with phorbol 12-myristate 13-acetate (PMA) in order to
differentiate them into macrophages (Riendeau and Kornfeld,
2003). PMA treatment of THP-1 cells causes the rearrangement
of macrophage-specific kinome that leads to the activation of pro-
inflammatory genes, such as IL-1β, IL-8 and TNF-α, making these
cells biased toward a more pro-inflammatory phenotype (Richter
et al., 2016). Furthermore, IL-1β has been shown to be a potent
stimulator of PAF C-16 synthesis in monocyte cell line, U-937
(Vlachogianni et al., 2013). In addition, PAF C-16 is known to
modulate the reduced and oxidised Glutathione ratio as well as
the redox status of monocytes (Verouti et al., 2011). Therefore, in
our study, THP-1 cells, untreated with PMA, were used to provide
a microenvironment in which the specific effect of PAF C-16 on
the growth of intracellular M. smegmatis could be examined.
PAF C-16 can activate monocytes/macrophages by binding
to PAFR (Simon et al., 1994) and stimulate the production of
inflammatory mediators such as TNF-α, IL-1α and β, reactive
oxygen intermediate (ROI) and reactive nitrogen intermediate
(RNI) species (Hartung et al., 1983; Bonavida et al., 1989;
Poubelle et al., 1991; Muehlmann et al., 2012), and thus may
play a protective role during infection. We have recently shown
that PAF C-16 and its analogs have direct inhibitory effect on
the growth of mycobacteria (Riaz et al., 2018). Therefore, we
investigated the effects of these compounds on mycobacterial
survival inside phagocytic cells, as these cells have the ability to
control mycobacterial infection when they are in an activated
state (Leemans et al., 2005). We hypothesized that PAF C-16
and its structurally related compounds may activate macrophages
to enhance its intracellular killing ability. In this study, PAF
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C-16 at an optimal dose of 1 µg/ml was shown to inhibit
M. smegmatis growth inside THP-1 cells, whereas any deviation
(increase or decrease) from this optimal concentration was
ineffective. This observation suggests that PAF C-16 acts in
a concentration-specific manner. This is consistent with a
previous study demonstrating that the treatment of human
macrophages with higher concentration (10−6 M) of PAF C-
16 showed reduced phagocytosis of Leishmania braziliensis as
compared to cells treated with the lower concentrations (10−8
and 10−10 M) (Borges et al., 2017). Similarly, human monocytes
showed maximum production of ROIs when stimulated with
PAF C-16 at 2 × 10−6 M; increasing the concentration of PAF
C-16 (5 × 10−6 M) led to a decrease in ROIs production
(Pustynnikov et al., 1991). The fact that PAF C-16 at higher
concentrations (5 µg and 10 µg/ml) showed less intracellular
growth inhibition than 1 µg/ml in our study, may be due to
higher level of PAFR down regulation at these concentrations, as a
result of the interaction of PAF C-16 with PAFR. This explanation
is supported by the observation made by Chao et al. (1990),
who showed that PAF C-16 binding to PAFR results in down
regulation of PAFRs in a dose-dependent manner on the surface
of rat Kupffer cells.
A number of previous studies have shown that exogenous PAF
C-16 can inhibit the growth of intracellular pathogens, including
Leishmania donovani (Lonardoni et al., 2000), Leishmania
braziliensis (Borges et al., 2017), Trypanosoma cruzi (Aliberti
et al., 1999), and Candida albicans (Im et al., 1997; Kim et al.,
2008) in vivo as well as in vitro. PAF C-16 induced growth
inhibition of these intracellular pathogens was shown to be
associated with an enhanced production of ROIs, RNIs, and
TNF-α. There is limited information regarding the effect of
PAF C-16 on the growth of intracellular mycobacteria. One
study investigating the role of endogenous PAF C-16 during
M.tb infection in mice found that there was no significant
difference in mortality between PAFR deficient (PAFR−/−) and
wild-type control mice when infected with M.tb and similar
M.tb loads were observed in the lungs and liver (Weijer
et al., 2003). However, to the best of our knowledge, there is
currently no information about the effect of exogenous PAF
C-16 or its structural analogs on the growth inhibition of
intracellular mycobacteria.
The biological activity of PAF C-16 in eukaryotic cells can
be affected by small modifications in its structure (Shigenobu
et al., 1985; O’Flaherty et al., 1987; Rose et al., 1990; Stewart
and Grigoriadis, 1991). Therefore, the effect of small changes in
the structure of PAF C-16 was also investigated on the growth
inhibition of intracellular M. smegmatis using different PAF C-
16 structure analogs. Lyso-PAF is the precursor form of PAF
C-16 that contains a hydroxyl group in place of the acetyl group
at sn-2 position of the glycerol backbone. The enzyme platelet-
activating factor acetylhydrolase (PAF-AH) tightly regulates the
level of active PAF C-16 in the body and converts excess PAF
C-16 into Lyso-PAF (McIntyre et al., 2009). Due to the inability of
Lyso-PAF to perform most of the biological functions associated
with PAF C-16, this precursor analog is mostly used as a control
in experiments performed with PAF C-16 (Montrucchio et al.,
2000). We observed that exogenous Lyso-PAF failed to inhibit
the growth of intracellular M. smegmatis, suggesting that the
acetyl group at position sn-2 was important for the intracellular
growth inhibitory effect of PAF C-16. Another synthetic PAF
C-16 analog, 2-O-methyl PAF (where acetyl group of PAF
C-16 at position sn-2 is replaced by a methyl group), was
also unable to inhibit the growth of intracellular M. smegmatis.
Structural analogs with changes in functional group at sn-2
position have previously been shown to lack different PAF C-16
associated activities such as aggregation of platelets (McManus
et al., 1981), NO production from endothelial cells (Kikuchi
et al., 2008), excitation of synaptic transmission in neuronal
cells (Clark et al., 1992), and bronchial hyper-responsiveness
(Cuss et al., 1986).
PAF C-18, a naturally occurring PAF C-16 analog,
was also used to investigate the effect of increase in the
number of carbon atoms in the aliphatic carbon tail on the
intracellular M. smegmatis growth inhibition. PAF C-18,
which has two additional carbon atoms in the aliphatic
carbon tail attached at position sn-1 as compared to PAF
C-16, was also able to inhibit the growth of intracellular
M. smegmatis. Previous studies have shown that PAF C-18
is less potent in inducing platelet aggregation but is as
potent as PAF C-16 in activating guinea pig macrophages
(Stewart and Grigoriadis, 1991).
Hexanolamino PAF differs from PAF C-16 in the position
of the terminal amino group, which is linked by an additional
4-carbon atoms chain to the phosphate group. This compound
also inhibited the growth of intracellular M. smegmatis.
Hexanolamino PAF has previously been shown to act as
both PAF C-16 antagonist and agonist. Hexanolamino
PAF can inhibit PAF C-16 stimulated production of ROI
by human macrophage (Rouis et al., 1988) and act as
a partial PAF C-16 agonist in guinea pig macrophages
(Stewart and Grigoriadis, 1991).
To investigate the role of PAF C-16 signaling through
PAFR during intracellular growth inhibition of M. smegmatis,
PAFR antagonists were used. PAFR antagonists are compounds
that can bind to PAFR and reduce PAF C-16 activity by
blocking PAFR (Singh et al., 2013). Prior treatment with PAFR
antagonists, ABT-491 or WEB-2086, increased the growth of
intracellular M. smegmatis as compared to the PAF C-16 only
treated condition, suggesting M. smegmatis intracellular growth
inhibition was partly mediated through PAFR. It has also
been suggested that PAF C-16 can perform certain biological
activities via pathways independent of PAFR signaling (Dyer
et al., 2010). PAFR antagonist, ABT-491, has been shown to
be highly effective in suppressing PAF C-16 induced platelet
degranulation and PAF C-16 mediated pathological conditions
such as inflammation, hypotension and other lethal effects in
rat and guinea pig models (Albert et al., 1997). Similarly,
WEB-2086 is also a known potent PAFR antagonist, which has
been shown to inhibit PAF C-16 induced activities such as
platelet aggregation, hypotension and vascular permeability in
rats (Clavijo et al., 2001).
Binding of PAF C-16 to PAFR results in the activation of
intracellular signaling components. Therefore, we investigated
the role of PAF C-16 intracellular signaling pathway components
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such as PLC, cPLA2 and different second messengers in PAF
C-16 induced growth inhibition of intracellular M. smegmatis.
Binding of PAF C-16 to PAFR on the target cell results in the
activation of a membrane bound enzyme, PLC, through the
associated G-proteins (Shukla, 1992). Treatment of M. smegmatis
infected THP-1 cells with PLC inhibitor, U-73122, increased
the number of surviving CFUs by 25.2%. During PAF C-16
signaling pathway, the activated PLC causes the hydrolysis of
phosphatidylinositol 4,5-bisphosphate (PIP2) and leads to the
production of second messengers, Diacylglycerol (DAG) and
Inositol triphosphate (IP3) (Ishii and Shimizu, 2000). Since these
second messengers are produced inside the cell and may come
in contact with the intracellular M. smegmatis, we investigated
PIP2 and DAG for their direct inhibitory effect on the growth
of M. smegmatis. However, both these compounds did not show
any direct inhibitory effect on the growth of M. smegmatis
when tested at a range of concentrations (5, 10, 25, 50 µg
and 100 µg/ml) (Supplementary Figures 3, 4), suggesting they
are not directly involved in the intracellular growth inhibition
activity of M. smegmatis.
PAF C-16 binding to PAFR also causes the activation of
cytosolic phospholipase A2 (cPLA2) due to increased levels
of intracellular Ca2+ (Ishii and Shimizu, 2000). Treatment
of M. smegmatis infected THP-1 cells with cPLA2 inhibitor,
Benzenesulfonamide, increased the surviving M. smegmatis
CFUs by 30% when compared to the M. smegmatis infected
THP-1 cells treated with PAF C-16 alone. Activated cPLA2
causes the production of AA from phospholipids inside
the cell (Nakashima et al., 1989). In our study, AA at a
concentration as low as 2.5 µg/ml (8.21 µM) significantly
reduced the number of surviving M. smegmatis CFUs in vitro.
This compound has previously been shown to inhibit the
growth of Staphylococcus aureus, Bacillus licheniformis, and
Streptococcus pyogenes (Raychowdhury et al., 1985; Zheng et al.,
2005). AA has also been shown to be present in resting
islet cells of Langerhans at a concentration of 15 µM/2000
cells, which increases to 10-fold after stimulation with carbacol
(Ramanadham et al., 1992). In normal human serum, AA is
present at a concentration of 500 nM/ml (Chilton et al., 1996),
whereas in lungs the AA concentration reported is 1–5 µg/ml
(Manku et al., 1983). Therefore, AA is available to interact
with both intra and extra-cellular pathogens. Collectively, these
results appear to suggest that PAF C-16 signaling via PAFR
leads to the production of an intermediate intracellular signaling
molecule, AA, which possesses direct growth inhibition capacity
and might be involved in the growth inhibition of intracellular
M. smegmatis. Furthermore, activation of cPLA2 leads to the
production of Lyso-PAF from the membrane lipids inside the
cell that can be converted into PAF C-16, resulting in its higher
intracellular concentration. It is also known that PAF C-16
can activate its own synthesis in human monocytes (Valone,
1991). This intracellular PAF C-16 can bind to its nuclear
receptors and elicit various signaling pathways resulting in the
expression of proinflammatory genes such as iNOS and COX-2
(Zhu et al., 2006).
Nitric oxide (NO) and RNIs such as peroxynitrite have
a damaging effect on mycobacteria (Long et al., 2005;
Jamaati et al., 2017). The role of RNIs in PAF C-16 induced
intracellular growth inhibition of M. smegmatis was investigated
by using a potent iNOS inhibitor, Aminoguanidine hemisulfate
(AG), which increased the survival of intracellular M. smegmatis
by 23.4% as compared to PAF C-16 only treated condition. PAF
C-16 has previously been shown to cause the production of NO
and RNIs in murine cells including monocytes, macrophages and
Kupffer cells through activation of iNOS enzyme (Szabo et al.,
1993; Mustafa et al., 1996). NO and related nitrogen compounds
have been shown to inhibit the growth of M.tb inside mouse
macrophages (Bose et al., 1999). Furthermore, it has been shown
that PAF C-16 treatment of T. cruzi infected mouse macrophages
results in the inhibition of intracellular parasite due to PAF C-16
induced NO production (Aliberti et al., 1999).
We also observed that TNF-α neutralizing antibody (anti-
TNF-α mAb) partially mitigated the growth inhibitory effect of
PAF C-16 on intracellular M. smegmatis. PAF C-16 has previously
been shown to stimulate macrophages to produce TNF-α (Dubois
et al., 1989; Ruis et al., 1991). The protective role of TNF-α during
M.tb infection is well established (Flynn et al., 1995; Keane et al.,
1997; Bean et al., 1999; Mohan et al., 2001). Previous studies
have shown that TNF-α is involved in the induction of NO
by activation of iNOS genes in macrophages, which causes the
elimination of intracellular pathogens such as L. major (Fonseca
et al., 2003) and T. cruzi (Silva et al., 1995).
In conclusion, our study shows that exogenous PAF C-16
can inhibit the intracellular growth of M. smegmatis involving
PAFR signaling pathways, which is at least partially mediated in a
NO and TNF-α dependent manner. The underlying mechanism
arising from this study is summarized in the Figure 10.
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